Project Grant R43CA306683
Award Date 8/11/26
Completion Date 7/31/27
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Carlsbad, CA 92011, USA
Similar Awards
- The National Cancer Institute awarded $668,878 to the University of Texas at Austin on April 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates targeting CD44 variant 9 for advanced and treatment-resistant breast cancer. The research addresses the clinical need for new therapeutic options for patients with triple-negative and heavily treated hormone receptor-positive metastatic breast cancer who have relapsed or progressed after current...
- The National Cancer Institute awarded Emory University $602,847 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the N-glycan modification pathway as a therapeutic target for triple-negative breast cancer, particularly in BRCA1-deficient patients. The project examines the role of MAN1C1, a glycosyl hydrolase, in breast cancer progression, immune evasion, and therapeutic resistance. The research addresses a critical gap: approximately 50–70 percent of...
- The National Cancer Institute awarded Virginia Commonwealth University $511,930 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify molecular determinants of response and resistance to TROP2-targeted antibody-drug conjugates and develop strategies to enhance therapeutic efficacy in triple-negative breast cancer and pancreatic adenocarcinoma. The project spans five years through July 31, 2031, with work performed in Richmond, Virginia. The research...
- The National Cancer Institute awarded Pearl Scientific Inc. $392,695 on September 18, 2025, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate humanized SEMA7A-antagonist monoclonal antibodies for the therapeutic treatment of breast cancer. Pearl Scientific will identify and validate humanized SEMA7A-antagonist monoclonal antibodies with high binding affinity, characterize their efficacy in blocking SEMA7A-mediated mechanisms and tumor growth, and assess their...
- The National Cancer Institute awarded the University of Southern California $426,828 under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2026, to identify potent anti-human CD1D antibodies and examine synergistic iNKT cell activation for metastatic melanoma immunotherapy. The project leverages novel human CD1D-knockin mouse models expressing human iNKT T cell receptor alpha chains to overcome prior translational barriers in anti-CD1D antibody development. Work aims to screen...
- The National Cancer Institute of the Department of Health and Human Services awarded $400,000 to Xtop Biotherapeutics Inc. on August 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to fund research and development of CB-101, a novel trispecific antibody targeting ROR1, EPCAM, and CD3 for treatment of colorectal cancer and other solid tumors. CB-101 is engineered using a proprietary crossbody platform designed to address limitations of existing T-cell engagers by reducing...
- The National Cancer Institute awarded Daybreak Pharmaceuticals Inc. $303,345 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a first-in-class synthetic RNA-based therapy targeting the mutagenic translesion synthesis pathway to enhance chemotherapy efficacy in non-small cell lung cancer. The project delivers proof-of-concept evaluation of translesion synthesis inhibition using a nucleic acid construct encoding a dominant-negative REV1 C-terminal...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $737,086 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate CDH17 as a therapeutic target in translocation renal cell carcinoma through T cell redirection therapy. The project, titled "From Biology to Therapy: Mechanism-Informed Targeting in Translocation Renal Cell Carcinoma," addresses an unmet medical need in a rare and aggressive RCC subtype driven by TFE3 gene fusion....
- The National Institutes of Health National Cancer Institute awarded Beth Israel Deaconess Medical Center, Inc. $430,521 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop, optimize, and validate novel monoclonal antibody tools for exploring altered glycosylation in tumor cells. The recipient will develop and validate TACA-specific (tumor-associated carbohydrate antigen-specific) monoclonal antibodies targeting dysregulated glycan expression on cancer cell...
- The National Cancer Institute awarded $400,000 to Toomer Therapeutics, Inc. on September 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small-molecule inhibitors of the E3 ubiquitin ligase ARIH1 as a targeted therapy for triple-negative breast cancer and other cancers. The project focuses on lead compound optimization, absorption-distribution-metabolism-excretion and pharmacokinetic studies to generate drug-like ARIH1 inhibitors, and preclinical efficacy studies of...